Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders.
Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders. Neuropsychopharmacology. 2021 09; 46(10):1802-1810.